Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)

12 Months Ended

Dec. 31, 2022

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS

Schedule of cash, cash equivalents and short-term investments

Cash, cash equivalents and short-term investments consisted of the following (in thousands):


	As of December 31,
	2022		2021
Cash	$	6,264	$	6,249
Money market funds		4,155		6,842
US treasury bills		5,225		35,366
Government-sponsored enterprise securities		15,796		14,678
Corporate bonds and commercial paper		26,766		61,832
	$	58,206	$	124,967
Reported as:
Cash and cash equivalents	$	24,459	$	18,890
Short-term investments		33,747		106,077
	$	58,206	$	124,967

Schedule of cash equivalents and short-term investments including securities with unrealized gains and losses


	As of December 31,
	2022		2021
Cash	$	6,264	$	6,249
Money market funds		4,155		6,842
US treasury bills		5,225		35,366
Government-sponsored enterprise securities		15,796		14,678
Corporate bonds and commercial paper		26,766		61,832
	$	58,206	$	124,967
Reported as:
Cash and cash equivalents	$	24,459	$	18,890
Short-term investments		33,747		106,077
	$	58,206	$	124,967

Schedule of fair value and gross unrealized losses of investments in unrealized loss position

The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):


As of December 31, 2022	Fair Value		Unrealized Losses
US treasury bills	$	5,225	$	(26)
Government-sponsored enterprise securities		14,322		(87)
Corporate bonds and commercial paper		26,766		(41)
Total	$	46,313	$	(154)